

INSight Alert



Shire backtracks on plan to Withdrawal Brand ProAmatine®

On September 7, 2010, the U.S. Food and Drug Administration announced that they have backtracked on the plan to remove ProAmatine from the market. The original decision to remove ProAmatine was announced on August 16, 2010 and was due to the manufacturer not having verified the clinical benefits of the drug. Since that time, numerous letters and emails from patients and healthcare providers flooded the FDA. ProAmatine is used to treat the low blood pressure condition, orthostatic hypotension.

The FDA will make sure that ProAmatine continues to be available to patients who use the drug, while it tries to resolve the issue that originally prompted the planned withdrawal: further postmarketing studies with the drug. Shire was planning to withdraw the drug from the market by September 30, 2010. The company no longer intends to do so.

In response to this announcement, FutureScripts/FutureScripts Secure will:

- Ensure that ProAmatine continues to process at the point-of-sale (POS)
- Send letters to all members who have received a notification of the withdrawal announcement, informing them that ProAmatine will continue to be available.
- Send letters to physicians, who were identified as having members under their care taking ProAmatine, informing them that ProAmatine will continue to be available.
- Electronically distribute an FS INSight Alert to our clients
- Post a Web Alert for our members and providers